Loading stock…

Galderma Group AG (GALD) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

GALDGalderma Group

Revenue FY25$5.2B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+86%10

EPS growth, FY27E+36%9

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 11%/yr over the last 3 years and is set to grow 18%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 36%/yr vs revenue 18%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

GALDGalderma Group

Total return Current75.0%

Price return Current74.9%

MOMENTUM RATING↗

STRONG73 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return-8%4

YTD return+0%5

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+11%6

3-year return+154%9

5-year return+154%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +154% over three years and +154% over five, ahead of 80% of the market.

It's up 11% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

Returns sit at the market level over three months (-8%) and so far this year (+0%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Galderma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GALDGalderma Group

Revenue FY25$5.2B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+86%10

EPS growth, FY27E+36%9

EPS growth, FY28E+34%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 11%/yr over the last 3 years and is set to grow 18%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 36%/yr vs revenue 18%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

GALDGalderma Group

Total return Current75.0%

Price return Current74.9%

MOMENTUM RATING↗

STRONG73 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return-8%4

YTD return+0%5

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+11%6

3-year return+154%9

5-year return+154%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +154% over three years and +154% over five, ahead of 80% of the market.

It's up 11% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

Returns sit at the market level over three months (-8%) and so far this year (+0%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Galderma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Galderma Group AG

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Galderma. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Galderma. Get the full investment case.

Premium